Dual & Triple Incretin Deal Benchmarks 2026
Market Analysis
Dual and triple incretin agonists represent the next frontier in obesity therapeutics. Tirzepatide (GLP-1/GIP dual agonist) demonstrated category-leading 22.5% weight loss, while retatrutide (GLP-1/GIP/glucagon triple agonist) achieved 24.2% weight loss in Phase 2 — the highest in any obesity trial. These multi-receptor approaches consistently outperform single-receptor GLP-1 agonists.
Phase 2 dual incretin licensing deals command median upfront payments of $1.6B, with total deal values of $7.6B. Triple agonists push even higher at $7.2B total value, reflecting the frontier premium and superior clinical data potential.
The Carmot/Roche acquisition at $2.7B for CT-388 (a GLP-1/GIP/FGF21 triple agonist at Phase 1) demonstrated the massive premium pharma will pay for next-generation multi-receptor approaches. Development milestones average $1.1B, with commercial milestones reaching $3.6B.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are dual incretin deals worth in 2026?
How do dual incretins compare to single GLP-1 agonists?
What milestone structures do incretin deals use?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.